Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol

Open access

Abstract

Objective: Reanalyse the patient-level data set of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study with fidelity to the original research protocol and related publications. Design: The study was open label and semirandomised examining the effectiveness of up to four optimised and increasingly aggressive, antidepressant therapies in depressed adults. Patients who failed to gain adequate relief from their level 1 trial on the SSRI citalopram could receive up to three additional treatment trials in levels 2–4. Setting: 41 North American psychiatry and primary care treatment centres. Participants: 4041 adults screened positive for major depressive disorder. In contrast to most clinical trials, STAR*D enrolled patients seeking care (vs recruited) and included patients with a wide range of common comorbid medical and psychiatric conditions to enhance the generalisability of findings to real-world clinical practice. Interventions: STAR*D evaluated the relative effectiveness of 13 antidepressants therapies in treatment levels 2–4 for depressed patients who failed to gain adequate benefit from their level 1 medication trial. Main outcome measures: According to the STAR*D protocol, the primary outcome was remission, defined as a score <8 on the blinded Hamilton Rating Scale for Depression (HRSD). Response was a secondary outcome defined as ≥50% reduction in HRSD scores. STAR*D’s protocol specifically excluded all non-blinded clinic-administered assessments from use as research outcome measures. Results: STAR*D investigators did not use the protocol-stipulated HRSD to report cumulative remission and response rates in their summary article and instead used a non-blinded clinic-administered assessment. This inflated their report of outcomes, as did their inclusion of 99 patients who scored as remitted on the HRSD at study outset as well as 125 who scored as remitted when initiating their next-level treatment. These patients should have been excluded from data analysis. In contrast to the STAR*D-reported 67% cumulative remission rate after up to four antidepressant treatment trials, the rate was 35.0% when using the protocol-stipulated HRSD and inclusion in data analysis criteria. Conclusion: STAR*D’s cumulative remission rate was approximately half of that reported.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2022-063095

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient flowchart. *In level 2, 580 patients were randomised to switch medications, 441 to medication augmentation, and 113 to cognitive therapy as either a switch or medication augmentation treatment. In level 2A, 28 patients were randomised to one of two level 2 switch medications. For step 3/level 3 patients, 186 were randomised to medication switch and 111 to medication augmentation. For step 4/level 3 patients, seven were randomised to medication switch and nine to medication augmentation. For step 4/level 4 patients, 90 were randomised to one of two medication/medication combination switch options. **Exit refers to the number of patients who exit the study and do not proceed either to the next treatment level nor enter follow-up. ***Follow-up refers to the number of patients who exit a treatment and enter the 12-month follow-up phase. HRSD, Hamilton Rating Scale for Depression.
Figure 1 Patient flowchart. *In level 2, 580 patients were randomised to switch medications, 441 to medication augmentation, and 113 to cognitive therapy as either a switch or medication augmentation treatment. In level 2A, 28 patients were randomised to one of two level 2 switch medications. For step 3/level 3 patients, 186 were randomised to medication switch and 111 to medication augmentation. For step 4/level 3 patients, seven were randomised to medication switch and nine to medication augmentation. For step 4/level 4 patients, 90 were randomised to one of two medication/medication combination switch options. **Exit refers to the number of patients who exit the study and do not proceed either to the next treatment level nor enter follow-up. ***Follow-up refers to the number of patients who exit a treatment and enter the 12-month follow-up phase. HRSD, Hamilton Rating Scale for Depression.CC BY-NC · PubMed Central
Figure 2 Comparison of STAR*D protocol predictions to what occurred. RIAT, Restoring Invisible and Abandoned Trial; STAR*D, Sequenced Treatment Alternatives to Relieve Depression.
Figure 2 Comparison of STAR*D protocol predictions to what occurred. RIAT, Restoring Invisible and Abandoned Trial; STAR*D, Sequenced Treatment Alternatives to Relieve Depression.CC BY-NC · PubMed Central
Figure 3 STAR*D’s step-by-step cumulative remission rate presented three ways. The step-by-step theoretical remission rates were obtained from the STAR*D summary article where it states: ‘The theoretical cumulative remission rate is 67% (37+19+6+5).’ [Rush AJ et al,7 p1910]. The HRSD+QIDS SR cumulative remission rate was taken from table 1. It combines the 1089 patients with an exit HRSD score of<8 with the 195 patients who were missing an exit HRSD score but had a final clinic-visit QIDS-SR score of<6. The RIAT Reanalysis cumulative remission rate is based on an exit HRSD score of <8 as the sole measure of remission for the 3110 patients who met STAR*D’s inclusion for data analysis criteria. HRSD, Hamilton Rating Scale for Depression; QIDS-SR, Quick Inventory of Depressive Symptomatology–Self Report; RIAT, Restoring Invisible and Abandoned Trial; STAR*D, Sequenced Treatment Alternatives to Relieve Depression.
Figure 3 STAR*D’s step-by-step cumulative remission rate presented three ways. The step-by-step theoretical remission rates were obtained from the STAR*D summary article where it states: ‘The theoretical cumulative remission rate is 67% (37+19+6+5).’ [Rush AJ et al,7 p1910]. The HRSD+QIDS SR cumulative remission rate was taken from table 1. It combines the 1089 patients with an exit HRSD score of<8 with the 195 patients who were missing an exit HRSD score but had a final clinic-visit QIDS-SR score of<6. The RIAT Reanalysis cumulative remission rate is based on an exit HRSD score of <8 as the sole measure of remission for the 3110 patients who met STAR*D’s inclusion for data analysis criteria. HRSD, Hamilton Rating Scale for Depression; QIDS-SR, Quick Inventory of Depressive Symptomatology–Self Report; RIAT, Restoring Invisible and Abandoned Trial; STAR*D, Sequenced Treatment Alternatives to Relieve Depression.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. 10.1176/appi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
  2. Pigott HE , Dubin W , Kirsch I , et al . Call to action: RIAT Reanalysis of the sequenced treatment alternatives to relieve depression (STAR*D) study. BMJ March 6, 2019. Available: https://www.bmj.com/content/346/bmj.f2865/rr-10

Cited by

See all 118

Metadata

Authors
Pigott, H. E., Kim, T., Xu, C., Kirsch, I., & Amsterdam, J.
Affiliations
  • None, Wakefield, Rhode Island, USA
  • University of Pennsylvania (US)
  • Harvard University (US)
Corresponding author
Pigott, H Edmund
Venue
BMJ Open
Publisher
BMJ
Published
2023-07
Volume
13
Issue
7
Pages
e063095
ISSN
2044-6055 (ISSN-L)
OpenAlex
W4385257581
Cited by
93
References
35
Citations by year
2026: 35 · 2025: 37 · 2024: 19 · 2023: 2
FWCI
14.64
Type
journal article
Language
en
Open access
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • HighWire Press Open Archive (submittedVersion)
Funders
The RIAT Support Center (N/A)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
major depressive disorder, antidepressant treatment, treatment remission, treatment response, Hamilton Depression Rating Scale, protocol fidelity, selective reporting, citalopram, antidepressant trials, real-world clinical practice
MeSH terms
Adult, Antidepressive Agents, Major Depressive Disorder, Depressive Disorder, Major, Humans, Psychotherapy, Citalopram, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol. https://app.cochat.ai/papers/10.1136/bmjopen-2022-063095
The paper
Pigott, H. E., Kim, T., Xu, C., Kirsch, I., & Amsterdam, J. (2023). What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol. BMJ Open. https://doi.org/10.1136/bmjopen-2022-063095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.